Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with rhGM-CSF and Thymosin Alpha 1 in Stage IV NSCLC
NCT02976740Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim and thymosin alpha 1 in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Abscopal Effect Rate. Status: unknown.
02
Drugs
sargramostimthymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02976740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976740.